onr:"swepub:oai:DiVA.org:uu-472740"
Search: onr:"swepub:oai:DiVA.org:uu-472740" > Expression of PD-1,...
- 1 of 1
- Previous record
- Next record
- To hitlist
| Fältnamn | Indikatorer | Metadata |
|---|---|---|
| 000 | 04527naa a2200445 4500 | |
| 001 | oai:DiVA.org:uu-472740 | |
| 003 | SwePub | |
| 008 | 220419s2022 | |||||||||||000 ||eng| | |
| 024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4727402 URI |
| 024 | 7 | a https://doi.org/10.3390/cancers140615092 DOI |
| 040 | a (SwePub)uu | |
| 041 | a engb eng | |
| 042 | 9 SwePub | |
| 072 | 7 | a ref2 swepub-contenttype |
| 072 | 7 | a art2 swepub-publicationtype |
| 100 | 1 | a Hellbacher, Eriku Uppsala universitet,Reumatologi4 aut0 (Swepub:uu)erihe902 |
| 245 | 1 0 | a Expression of PD-1, PD-L1 and PD-L2 in Lymphomas in Patients with Pre-Existing Rheumatic Diseases-A Possible Association with High Rheumatoid Arthritis Disease Activity |
| 264 | c 2022-03-15 | |
| 264 | 1 | b MDPI,c 2022 |
| 338 | a electronic2 rdacarrier | |
| 520 | a Simple Summary Immunotherapy blocking programmed cell death protein 1 (PD-1) and its ligands (PD-L1, PD-L2) is less effective in non-Hodgkin lymphoma (NHL) than classical Hodgkin lymphoma. However, NHL is a heterogeneous group and current research seeks to identify subgroups of NHL patients responsive to PD-1 blocking agents. Whether patients with pre-existing rheumatic diseases might constitute such a subgroup is unknown. We investigated the expression of PD-1 and its ligands in lymphoma patients with pre-existing rheumatic diseases. Our key findings include that in patients with pre-existing rheumatoid arthritis (RA) and subsequent diffuse large B-cell lymphoma, an association between RA disease severity and increased expression of PD-L1 in tumor cells was seen. This warrants further studies of the PD-1 pathway in lymphoma in other chronic inflammatory conditions. Current research seeks to identify subgroups of non-Hodgkin lymphoma (NHL) patients responsive to PD-1 blocking agents. Whether patients with pre-existing rheumatic diseases might constitute such a subgroup is unknown. We determined intratumoral expression of PD-1 and its ligands in lymphoma patients with pre-existing rheumatic diseases. We included 215 patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) or Sjogren's syndrome with subsequent lymphoma and 74 diffuse large B-cell lymphoma (DLBCL) controls without rheumatic disease. PD-1 and PD-ligand immunohistochemical markers were applied on tumor tissue microarrays. The number of PD-1+ tumor infiltrating leukocytes (TILs) and proportions of PD-L1+ and PD-L2+ tumor cells and TILs were calculated and correlated with clinical data. Expression of PD-L1 in tumor cells and TILs was highest in classical Hodgkin lymphoma and DLBCL. In DLBCLs, expression of PD-1 in TILs and PD-L1 in tumor cells was similar in RA, SLE and controls. In RA-DLBCL, high expression of PD-L1 in tumor cells was significantly more common in patients with the most severe RA disease and was associated with inferior overall survival in multivariable analysis. | |
| 650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Reumatologi och inflammation0 (SwePub)302102 hsv//swe |
| 650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Rheumatology and Autoimmunity0 (SwePub)302102 hsv//eng |
| 650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
| 650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
| 653 | a lymphoma | |
| 653 | a PD-1 | |
| 653 | a PD-L1 | |
| 653 | a rheumatic disease | |
| 653 | a immunohistochemistry | |
| 700 | 1 | a Sundström, Christeru Uppsala universitet,Experimentell och klinisk onkologi,Klinisk och experimentell patologi,Science for Life Laboratory, SciLifeLab4 aut0 (Swepub:uu)chrisund |
| 700 | 1 | a Molin, Daniel,d 1969-u Uppsala universitet,Experimentell och klinisk onkologi4 aut0 (Swepub:uu)danimoli |
| 700 | 1 | a Baecklund, Eva,d 1956-u Uppsala universitet,Reumatologi,Science for Life Laboratory, SciLifeLab4 aut0 (Swepub:uu)evaba786 |
| 700 | 1 | a Hollander, Peteru Uppsala universitet,Experimentell och klinisk onkologi,Klinisk och experimentell patologi4 aut0 (Swepub:uu)petho189 |
| 710 | 2 | a Uppsala universitetb Reumatologi4 org |
| 773 | 0 | t Cancersd : MDPIg 14:6q 14:6x 2072-6694 |
| 856 | 4 | u https://doi.org/10.3390/cancers14061509y Fulltext |
| 856 | 4 | u https://uu.diva-portal.org/smash/get/diva2:1652665/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print |
| 856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-472740 |
| 856 | 4 8 | u https://doi.org/10.3390/cancers14061509 |
- 1 of 1
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Hellbacher, Erik
- Sundström, Chris ...
- Molin, Daniel, 1 ...
- Baecklund, Eva, ...
- Hollander, Peter
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- and Rheumatology and ...
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- and Cancer and Oncol ...
- Articles in the publication
- Cancers
- By the university
- Uppsala University
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
